Use of basiliximab induction in low-immunological risk renal transplant recipients receiving XXXX -based immunosuppression.

@entity1 @entity1011 @entity281 @entity1140
Basiliximab induction treatment has been shown to reduce the incidence of acute rejection episodes without the secondary side effects observed with antilymphocyte polyclonal antibodies. We analyzed our experience with basiliximab induction associated with @entity1140 -based immunosuppression among low-immunological risk renal transplant recipients. We retrospectively analyzed 55 renal transplantation @entity1 of low inmunological risk who received organs from donors younger than 55 years. We compared a group of 21 @entity1 (38.9%; group 1) treated with basiliximab (Simulect, Novartis, Basel, Switzerland) with 33 @entity1 (61.1%; group 2) without induction. The @entity1 groups did not differ in recipient age (46.39 +/- 11.1 in group 1 vs 41.82 +/- 11.02 years in group 2; P = .25), donor age (36.71 +/- 14.72 vs 35.09 +/- 14.63 years; P = .69), or recipient and donor gender. No differences were observed in dose or @entity1140 levels during follow-up. The incidences of delayed graft function (DGF; 28.6% vs 28.1%; P = .97) and of acute rejection episodes (9.5% vs 15.6%; P = .52) were similar in both groups. Serum @entity1011 and proteinuria levels (P > .05) and hospital admissions due to @entity281 (36.4 vs 35.7%; P = .97) were also similar in both groups. At 1 year graft survival rates were 92% and 96% (P = .97) in groups 1 and 2, respectively. Considering our findings and the costs of basiliximab treatment, we conclude that routine administration of basiliximab cannot be justified in young, low-immunological risk transplant recipients undergoing @entity1140 -based immunosuppression.
